lobbying_activities: 398843
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 398843 | 7f64ced7-f883-47a7-8944-f5a392282d02 | YY | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | CHIRON CORP | 2005 | year_end | CPT | H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect intellectual property rights. H.R. 2791: To amend title 35, United States Code, with respect to patent fees, and for other purposes. Lobbied for reasonable patent fees and to protect intellectual property rights.H.R. 357, S. 167: To provide for the protection of intellectual property rights, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4102: To amend title 35, United States Code, to provide for compulsory licensing of certain patented inventions relating to health care emergencies. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4131: To amend title 35, United States Code. to provide for compulsory licensing of certain patented inventions relating to health care emergencies, and to provide that applications under section 505 of the Federal Food, Drug, and Cosmetic Act that are submitted pursuant to such licenses may be approved with immediate effective dates. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 4392: To provide for the importation of pharmaceutical products under a compulsory license as provided for under the World Trade Organization. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. S. 167: a bill to provide for the protection of intellectual property rights, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. S. 1511: A bill to clarify that the overall trade negotiating objectives of the United States include avoiding provisions in trade agreements that restrict the access of consumers in the United states to pharmaceutical imports, and for other purposes. Lobbied to protect the Biopharmaceutical indistry's intellectual property rights. S.Amdt. to H.R. 2862: To prevent the United States Trade Representative from negotiating future trade agreements that prevent the United States from changing United States patent law to allow the importation of pharmaceutical products. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. | Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 100000 | 0 | 0 | 2006-02-10T00:00:00-05:00 |